Equis ISSN 2398-2977

Suxibuzone

Contributor(s): Adam Auckburally, Ruth Morgan

Introduction

Name

  • Suxibuzone.

Class of drug

  • Non-steroidal anti-inflammatory drug.
  • Pyrazolidine.

Description

Chemical name

  • 4-[[4-butyl-3,5-dioxo-1,2-di(phenyl)pyrazolidin-4-yl]methoxy]-4-oxobutanoic acid.

Molecular formula

  • C24H26N2O6.

Molecular weight

  • 438.437 g.

Physical properties

  • Yellow odorless granules; each 10 g sachet contains 1.5 g suxibuzone (microencapsulated) in combination with quinoline yellow (E104).

Storage requirements

  • No special storage requirements reported by manufacturer.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Licensed in the UK for the treatment of pain and inflammation associated with musculoskeletal conditions in the horse.
  • Examples given by the manufacturer are osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmacokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Do not administer with other NSAIDs or corticosteroids Therapeutics: anti-inflammatory drugs.
  • May compete for protein binding sites leading to increased plasma concentrations of free drug and toxic effects. Reported examples of highly protein bound drugs which may be displaced by NSAIDs are oral anticoagulants, glucocorticoids, sulfonamides Therapeutics: sulfonamides, methotrexate Methotrexate, valproic acid and phenytoin Phenytoin.
  • Concurrent administration of other nephrotoxic drugs should be avoided.
  • Avoid co-administration with anticoagulant drugs.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Sabate D, Homedes J, Salichs M et al (2009) Multicentre, controlled, randomised and blinded field study comparing efficacy of suxibuzone and phenylbutazone in lame horses. Equine Vet J 41 (7), 700-705 PubMed.
  • Jaraiz V, Rodriguez C & San Andres M D (1999) Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses. J Vet Pharm Ther 22 (4), 247-254 PubMed.
  • Homedes J, Sabate D & Mayos I (1997) General and gastrointestinal tolerance of suxibuzone orally administered to horses, compared to phenylbutazone. J Vet Pharm Ther 20 (Supp 1), 163-164.
  • Sabate D, Homedes J & Mayos I (1997) Comparative study of the clinical efficacy of suxibuzone and phenylbutazone in the treatment of musculoskeletal inflammatory disorders in horses. J Vet Pharm Ther 20, 162-163.
  • Delbeke F T, Vynckier L & Debackere M (1993) The disposition of suxibuzone in the horse. J Vet Pharm Ther 16 (3), 283-290 PubMed.
  • Tobin T, Chay S & Kamerling S (1986) Phenylbutazone in the horse: a review. J Vet Pharm Ther 9, 1-25.

Other sources of information

  • Kollias-Baker C & Cox K (2004) Non-steroidal Anti-inflammatory Drugs. In: Equine Clinical Pharmacology. Eds: Bertone J J & Horspool L J I. Saunders Elsevier, USA. pp 247-266.
  • Danilon Equidos® SPC.

ADDED